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BACKGROUND: Some trials have found that patients from the United 
States derive less benefit than patients enrolled outside the United States. 
This prespecified REDUCE-IT (Reduction of Cardiovascular Events with 
Icosapent Ethyl - Intervention Trial) subgroup analysis was conducted to 
determine the degree of benefit of icosapent ethyl in the United States.
METHODS: REDUCE-IT randomized 8179 statin-treated patients 
with qualifying triglycerides ≥135 and <500 mg/dL and low-density 
lipoprotein cholesterol >40 and ≤100 mg/dL and a history of 
atherosclerosis or diabetes mellitus to icosapent ethyl 4 g/d or placebo. 
The primary composite end point was cardiovascular death, nonfatal 
myocardial infarction, nonfatal stroke, coronary revascularization, or 
hospitalization for unstable angina. The key secondary composite 
end point was cardiovascular death, nonfatal myocardial infarction, or 
nonfatal stroke. A hierarchy was prespecified for examination of individual 
and composite end points.
RESULTS: A total of 3146 US patients (38.5% of the trial) were randomized 
and followed for a median of 4.9 years; 32.3% were women and 9.7% 
were Hispanic. The primary composite end point occurred in 24.7% of 
placebo-treated patients versus 18.2% of icosapent ethyl-treated patients 
(hazard ratio [HR], 0.69 [95% CI, 0.59–0.80]; P=0.000001); the key 
secondary composite end point occurred in 16.6% versus 12.1% (HR, 0.69 
[95% CI, 0.57–0.83]; P=0.00008). All prespecified hierarchical end points 
were meaningfully and significantly reduced, including cardiovascular death 
(6.7% to 4.7%; HR, 0.66 [95% CI, 0.49–0.90]; P=0.007), myocardial 
infarction (8.8% to 6.7%; HR, 0.72 [95% CI, 0.56–0.93]; P=0.01), stroke 
(4.1% to 2.6%; HR, 0.63 [95% CI, 0.43–0.93]; P=0.02), and all-cause 
mortality (9.8% to 7.2%; HR, 0.70 [95% CI, 0.55–0.90]; P=0.004); for all-
cause mortality in the US versus non-US patients, Pinteraction=0.02. Safety and 
tolerability findings were consistent with the full study cohort.
CONCLUSIONS: Whereas the non-US subgroup showed significant 
reductions in the primary and key secondary end points, the US subgroup 
demonstrated particularly robust risk reductions across a variety of 
individual and composite end points, including all-cause mortality.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. 
Unique identifier: NCT01492361.
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Triglyceride elevation is a potent marker of resid-ual cardiovascular risk in patients with well-con-trolled low-density lipoprotein cholesterol (LDL-
C) on statin therapy, as shown in both randomized 
statin trials and observational studies.1–3 REDUCE-IT 
(Reduction of Cardiovascular Events With Icosapent 
Ethyl–Intervention Trial) addressed this residual risk, 
finding a significant 25% relative risk reduction in 
first ischemic events with icosapent ethyl 4 g/d versus 
placebo in statin-treated patients with triglycerides 
>~135 mg/dL.4–7 This included a statistically signifi-
cant 20% relative risk reduction in death attribut-
able to cardiovascular causes, similar rates of non-
cardiovascular deaths, and therefore a trend towards 
lower all-cause mortality (13% relative risk reduction, 
P=0.09).4 Analysis of total ischemic events (first and 
subsequent events) found a significant 30% reduc-
tion, with consistent benefits across baseline and 
achieved triglyceride levels.5–9 In light of the strong 
results in REDUCE-IT, several national and internation-
al guidelines have incorporated icosapent ethyl into 
their recommendations.10–13 The results of REDUCE-IT 
appear to be generalizable to a sizable proportion of 
high-risk secondary and primary prevention popula-
tions.14 Trial-level analysis shows icosapent ethyl to be 
highly cost-effective.15
In the United States, there are at least 70 million pa-
tients with triglycerides ≥135 mg/dL, with >15 million 
of those on statins, and >7 million of those with LDL-
C controlled to <100 mg/dL. It is estimated that there 
are almost 5 million US patients who fit the REDUCE-IT 
patient profile: statin-treated with diabetes mellitus or 
established cardiovascular disease who are ≥45 years of 
age with LDL-C <100 mg/dL.16,17 Thus, there is substan-
tial residual risk in these patients that potentially could 
be addressed if they were identified and treated with 
icosapent ethyl.18
International trials of various pharmacotherapies 
have sometimes found discordant results in patients 
enrolled in the United States than seen in overall trial 
results.19–32 The reasons range from low numbers of 
patients enrolled in the United States to potential dif-
ferences in background medical management or in pa-
tient risk profiles. We sought to explore the prespeci-
fied subgroup of patients from REDUCE-IT enrolled in 
the United States to determine the effects of icosapent 
ethyl in this subgroup.
METHODS
The data that support the findings of this study may be made 
available from the corresponding author upon reasonable 
request. The details of the REDUCE-IT design have been pub-
lished previously.4,5,33 Patients were randomized in a double-
blind fashion to either icosapent ethyl 4 g/d (2 grams twice 
daily with meals) or matching placebo. The protocol was 
approved by health authorities, ethics committees, and insti-
tutional review boards; procedures were followed in accor-
dance with institutional guidelines, and participants gave 
written informed consent. Patients were required to be either 
≥45 years of age with established cardiovascular disease (sec-
ondary prevention stratum) or ≥50 years of age with diabe-
tes mellitus and at least 1 additional cardiovascular risk factor 
(primary prevention stratum).
To qualify, patients were required to have fasting triglyc-
erides of ≥135 mg/dL and <500 mg/dL and LDL-C >40 mg/
dL and ≤100 mg/dL. Patients were required to be on stable 
statin therapy for at least 4 weeks with well-controlled LDL-
C. Because of variability in fasting triglyceride levels, baseline 
was defined as an average of each patient’s qualifying triglyc-
eride level and randomization day level; these baseline values 
ranged from 81 mg/dL to 1401 mg/dL.
The primary end point was the first occurrence of the com-
posite of cardiovascular death, nonfatal myocardial infarction 
(MI), nonfatal stroke, coronary revascularization, or hospital-
ization for unstable angina. The key secondary end point was 
the composite of cardiovascular death, nonfatal MI, or non-
fatal stroke. A hierarchical testing sequence of individual and 
composite end points was prespecified. All end points were 
adjudicated by an independent clinical end point committee 
blinded to treatment.
Clinical Perspective
What Is New?
• REDUCE-IT (Reduction of Cardiovascular Events 
With Icosapent Ethyl–Intervention Trial) USA found 
that icosapent ethyl 4 g/d produced large and sig-
nificant reductions in multiple ischemic end points, 
including cardiovascular death, myocardial infarc-
tion, stroke, coronary revascularization, and hospi-
talization for unstable angina.
• REDUCE-IT USA demonstrated that icosapent ethyl 
provided a statistically significant 30% relative risk 
reduction and 2.6% absolute risk reduction in all-
cause mortality.
• The risk-benefit profile of icosapent ethyl was 
highly favorable, with an overall safety and toler-
ability profile virtually identical to that of placebo.
What Are the Clinical Implications?
• Use of icosapent ethyl in eligible secondary and 
primary prevention patients would be expected to 
have a substantial benefit in reducing residual car-
diovascular risk.
• Several international guidelines have embraced the 
REDUCE-IT data, an independent analysis has found 
it to be highly cost-effective, and multiple registry 
analyses show the data are generalizable to a large 
number of patients in typical clinical practice.
• Health care systems should implement the results 
of REDUCE-IT without delay in order to reduce 
the burden of initial and subsequent cardiovascu-
lar events that patients face  with even modestly 
elevated triglycerides.
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Statistical Analysis
For the present prespecified analysis, the effects of icosapent 
ethyl versus placebo were examined in patients randomized 
in the United States. Demographic and baseline character-
istics were compared between treatment groups using the 
chi-square test for categorical variables and the Wilcoxon rank-
sum test for continuous variables. Time to first occurrences of 
the primary and the secondary efficacy end points in the pre-
specified testing hierarchy were analyzed using a Kaplan-Meier 
analysis stratified by cardiovascular risk category and base-
line ezetimibe use. Hazard ratios (HRs) and 95% confidence 
intervals (CIs) were generated from a corresponding stratified 
Cox proportional-hazards regression model. Heterogeneity of 
treatment effects between the US and non-US subgroups was 
examined by testing the interaction term of treatment by US 
versus non-US subgroup in the Cox regression model. Total 
(first and recurrent) cardiovascular events for the primary and 
key secondary composite end points were also analyzed using 
a negative binomial regression model to calculate rates and 
rate ratios, accounting for variability in each patient’s risk of 
events. Efficacy analyses were performed in accordance with 
the intention-to-treat principle, and all tests were based on a 
2-sided significance level of 0.05. P values presented are nomi-
nal and exploratory with no adjustment for multiple compari-
sons. Statistical analyses were performed using SAS software, 
version 9.4 (SAS Institute, Cary, NC).
RESULTS
Population Characteristics
A total of 6962 patients were screened in the Unit-
ed States. Of these, 3146 US patients (45% of those 
screened; 38.5% of the overall trial) were randomized 
and followed for a median of 4.9 years (maximum 
follow-up 6.2 years). Further details regarding the dis-
position of the patients are provided in Figure I in the 
online-only Data Supplement. Baseline characteristics in 
the United States were generally similar to the overall 
population (Table I in the online-only Data Supplement). 
Of the US patients, 92.5% were white, 32.3% were 
women, and 9.7% were Hispanic (Table). Patient char-
acteristics were generally well-balanced between the 2 
treatment groups. Table I in the online-only Data Sup-
plement shows the US versus non-US subgroups. As ex-
pected, there were several baseline differences between 
them, such as greater age, higher proportion of women, 
higher body mass index, more diabetes mellitus, lower 
LDL-C, and lower eicosapentaenoic acid levels in the US 
subgroup. There were no significant between-group dif-
ferences in baseline triglyceride levels. A higher propor-
tion of US patients were in the primary prevention stra-
tum; within the US subgroup, 58.8% of patients were 
randomized into the secondary prevention cohort and 
41.2% into the primary prevention cohort. US placebo-
treated patients had a higher primary end point event 
rate compared with the non-US group (67.4 versus 51.5 
per 1000 patient-years, respectively; P=0.001). Overall, 
US placebo-treated patients in the secondary prevention 
cohort had a higher primary event rate compared with 
non-US placebo-treated patients (93.2 versus 58.7 per 
1000 patient-years, respectively). Similarly, for the pri-
mary prevention cohort, primary end point event rates 
were higher in the US placebo-treated patients com-
pared with the non-US placebo-treated patients (35.8 
versus 28.9 per 1000 patient-years, respectively).
Efficacy End points
In the US cohort, the primary composite end point oc-
curred in 24.7% of placebo-treated versus 18.2% of 
icosapent ethyl-treated patients (HR, 0.69 [95% CI, 
0.59–0.80]; P=0.000001; number needed to treat [NNT], 
15) (Figure 1). The key secondary composite end point 
occurred in 16.6% versus 12.1% (HR, 0.69 [95% CI, 
0.57–0.83]; P=0.00008; NNT, 22) (Figure 2). All prespec-
ified end points in the testing hierarchy were reduced 
significantly, including cardiovascular death (6.7% to 
4.7%; HR, 0.66 [95% CI, 0.49–0.90]; P=0.007), MI 
(8.8% to 6.7%; HR, 0.72 [95% CI, 0.56–0.93]; P=0.01), 
stroke (4.1% to 2.6%; HR, 0.63 [95% CI, 0.43–0.93]; 
P=0.02), and all-cause mortality (9.8% to 7.2%; HR, 
0.70 [95% CI, 0.55–0.90]; P=0.004) (Figures 3 and 4). 
The results for the US versus non-US subgroups in the 
above end points were generally consistent (Figure II in 
the online-only Data Supplement). For the primary ef-
ficacy end point, the HR outside the United States was 
0.80 (95% CI, 0.71–0.91; P=0.0008; Pinteraction=0.14); for 
the key secondary efficacy end point, the HR outside the 
United States was 0.77 (95% CI, 0.66–0.91; P=0.001; 
Pinteraction=0.38). The interaction P value of all-cause mor-
tality was 0.02.
The primary efficacy end  point and key second-
ary efficacy end  point results were generally consis-
tent across the subgroups of US patients  examined, 
including sex, race, and ethnicity (Figures III and IV in 
the online-only Data Supplement). The proportion of 
first (53% of total events) and subsequent ischemic 
events (47% of total events) is shown in Figure V in 
the online-only Data Supplement. Figures VI and VII 
in the online-only Data Supplement show the sig-
nificant reductions in not only first, but also second, 
third, and total events. The Kaplan-Meier event curves 
are depicted for total (first and subsequent) ischemic 
events in Figures VIII and IX in the online-only Data 
Supplement, demonstrating large, statistically signifi-
cant reductions in the primary (rate ratio, 0.68 [95% 
CI, 0.57–0.82]; P=0.00002) and key secondary (rate 
ratio, 0.68 [95% CI, 0.55–0.83]; P=0.0002) efficacy 
end points. Figure X in the online-only Data Supple-
ment depicts the number of events per 1000 patients 
treated for 5 years with icosapent ethyl versus place-
bo, with 204 total primary composite end point events 
prevented, as well as 34 deaths of any cause.
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Table. Patient Characteristics at Baseline
Baseline Parameter* Icosapent Ethyl (n=1548) Placebo (n=1598) P Value†
Age, y 65.0 (59.0–71.0) 65.0 (59.0–71.0) 0.56
Age ≥65 y 808 (52.2) 866 (54.2) 0.26
Female 487 (31.5) 528 (33.0) 0.34
BMI, kg/m2 32.3 (28.8–36.5) 32.2 (28.7–36.6) 0.54
Hispanic or Latino 165 (10.7) 141 (8.8) 0.08
Race‡ 0.29
  White 1437 (92.8) 1474 (92.2)  
  Black or African American 52 (3.4) 72 (4.5)  
  Asian 35 (2.3) 34 (2.1)  
  Other or multiple 24 (1.6) 18 (1.1)  
Stratification factors other than geography
  Cardiovascular risk category as randomized 0.87
  Secondary prevention 908 (58.7) 942 (58.9)  
   Primary prevention 640 (41.3) 656 (41.1)  
  Ezetimibe use 94 (6.1) 108 (6.8) 0.43
Statin intensity and diabetes mellitus status
  Statin intensity 0.64
   Low 152 (9.8) 153 (9.6)  
   Moderate 871 (56.3) 923 (57.8)  
   High 518 (33.5) 511 (32.0)  
   Missing 7 (0.5) 11 (0.7)  
  Diabetes mellitus 0.37
   Type I 12 (0.8) 20 (1.3)  
   Type II 1078 (69.6) 1095 (68.5)  
   None 458 (29.6) 483 (30.2)  
Laboratory measurements
  Creatinine clearance >30 and <60 mL/min 187 (12.1) 202 (12.6) 0.67
  hsCRP, mg/L 2.5 (1.2–5.0) 2.4 (1.2–5.1) 0.71
  Triglycerides, mg/dL 217.0 (177.5–271.0) 217.5 (175.0–273.5) 0.93
  Triglycerides category, mg/dL 0.92
   <150 161 (10.4) 172 (10.8)  
   150–<200 439 (28.4) 446 (27.9)  
   ≥200 945 (61.0) 979 (61.3)  
  HDL-C, mg/dL 39.5 (34.0–45.5) 40.0 (34.5–46.5) 0.06
  LDL-C, mg/dL 72.0 (60.0–85.0) 73.0 (61.0–85.0) 0.27
  LDL-C tertiles, mg/dL 0.31
   Lowest (≥1–≤67) 639 (41.3) 620 (38.8)  
   Middle (>67–≤84) 517 (33.4) 568 (35.5)  
   Upper (>84–≤222) 389 (25.1) 409 (25.6)  
  EPA, µg/mL 20.8 (15.1–28.4) 21.9 (15.5–29.1) 0.04
Cardiovascular disease history§
  Atherosclerotic coronary artery disease and 
related morbidities
712 (46.0) 734 (45.9) 0.97
  Atherosclerotic cerebrovascular disease and 
related morbidities
273 (17.6) 300 (18.8) 0.41
  Atherosclerotic peripheral artery disease 131 (8.5) 160 (10.0) 0.13
(Continued )
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Tolerability and Safety
Tolerability and safety findings in the US cohort were 
consistent with the full study cohort. There were no 
significant differences in the rates of adherence to 
double-blind treatment between icosapent ethyl-
treated and placebo-treated patients. There were no 
significant differences between icosapent ethyl and 
placebo in overall treatment-emergent adverse event 
rates (Table II in the online-only Data Supplement). 
Serious treatment-emergent adverse events occurred 
in 34.4% of participants treated with icosapent ethyl 
versus 35.7% treated with placebo (P=0.46). Regard-
ing overall  treatment-emergent gastrointestinal dis-
orders, there was no treatment difference (40.4% 
versus 42.6%; P=0.21); diarrhea was less frequent 
with icosapent ethyl versus placebo (10.3% versus 
13.0%; P=0.02), constipation was more frequent 
(7.8% versus 5.1%; P=0.002), dysphagia was more 
frequent (2.2% versus 1.1%; P=0.02), and eructation 
was more frequent (1.2% versus 0.4%; P=0.008). In-
formation regarding atrial fibrillation or flutter is pre-
sented in Table III in the online-only Data Supplement. 
Treatment-emergent atrial fibrillation/flutter adverse 
events (exclusive of those  positively adjudicated as 
end points) occurred in 6.6% of the icosapent ethyl 
group and 4.5% of the placebo group (P=0.01); posi-
tively adjudicated end points of atrial fibrillation/flut-
ter requiring hospitalization for 24 or more hours oc-
curred in 3.6% versus 2.9% of participants (P=0.35). 
Bleeding results are summarized in Tables IV and V 
in the online-only Data Supplement. Bleeding treat-
ment-emergent adverse events of any type (exclusive 
of positively adjudicated hemorrhagic stroke events 
which were accounted for as trial end points) oc-
curred in 16.7% of the icosapent ethyl group versus 
13.6% of the placebo group (P=0.02), with no signif-
icant difference in central nervous system or gastro-
intestinal bleeding. Serious bleeding adverse events 
Medications taken at baseline
  Antidiabetic 1020 (65.9) 1056 (66.1) 0.91
  Antihypertensive 1468 (94.8) 1515 (94.8) 0.97
  Antiplatelet‖ 1220 (78.8) 1228 (76.8) 0.18
   1 861 (55.6) 867 (54.3) 0.44
   ≥2 359 (23.2) 361 (22.6) 0.69
  Anticoagulant 139 (9.0) 164 (10.3) 0.22
  Anticoagulant plus antiplatelet 71 (4.6) 85 (5.3) 0.34
  No antithrombotic 260 (16.8) 291 (18.2) 0.3
  ACE inhibitor 804 (51.9) 838 (52.4) 0.78
  ARB 396 (25.6) 395 (24.7) 0.58
  ACE inhibitor or ARB 1178 (76.1) 1217 (76.2) 0.97
  β-blocker 1036 (66.9) 1030 (64.5) 0.14
  Statin 1541 (99.5) 1587 (99.3) 0.38
Values are median (Q1–Q3) or n (%). Percentages are based on the number of participants randomized to each treatment 
group in the United States (N). In general, the baseline value is defined as the last nonmissing measurement obtained before 
randomization. The baseline LDL-C value obtained through preparative ultracentrifugation was used, unless this value was 
missing. If the LDL-C preparative ultracentrifugation value was missing, then another LDL-C value was used, with prioritization 
of values obtained from LDL-C direct measurements, followed by LDL-C derived by the Friedewald calculation method (only 
for participants with triglycerides <400 mg/dL), and LDL-C derived using the calculation published by investigators at The 
Johns Hopkins University. For all other lipid and lipoprotein marker parameters, wherever possible, baseline was derived as the 
arithmetic mean of the randomization visit 2 (day 0) value and the preceding visit 1 (or visit 1.1) value. If only one of these values 
was available, the single available value was used as baseline. Tertiles for LDL-C derived and triglycerides are based on the overall 
intention-to-treat population. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blockers; BMI, body 
mass index; EPA, eicosapentaenoic acid; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reaction protein; 
and LDL-C, low-density lipoprotein cholesterol.
*Additional baseline parameters, including US, non-US, and overall cohorts, are provided in Table I in the online-only Data 
Supplement.
†P values are reported from a chi-square test for categorical variables and Wilcoxon rank-sum test for continuous variables. 
Missing categories are excluded from any comparisons.
‡P value is based on the race categories as listed herein. The category “other or multiple” also includes American Indian, 
Alaskan Native, Native Hawaiian, and Other Pacific Islander.
§The summary is based on the data collected from the cardiovascular history case report form.
‖Antiplatelet medications were classified as dual if both components have a regulatory approval affirming antiplatelet effects. 
Combinations in which one element lacks such regulatory approval were excluded (eg, aspirin + magnesium oxide is classified as 
a single agent because the latter component is not FDA-approved as an antiplatelet agent).
Table. Continued
Baseline Parameter* Icosapent Ethyl (N=1548) Placebo (N=1598) P Value†
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occurred in 3.6% of the icosapent ethyl group versus 
3.3% of the placebo group (P=0.77).
DISCUSSION
In this prespecified analysis of the 3146 patients en-
rolled into REDUCE-IT in the United States, for the pri-
mary composite end point  there was a 31% relative 
risk reduction and 6.5% absolute risk reduction in first 
ischemic events (NNT, 15). The key secondary com-
posite end point of cardiovascular death, nonfatal MI, 
or nonfatal  stroke was also reduced by 31%, with a 
4.6% absolute risk reduction (NNT, 22). Significant re-
ductions in all composite and individual end points in 
the prespecified testing hierarchy were also observed, 
including cardiovascular death, MI, stroke, coronary 
revascularization, or hospitalization for unstable an-
gina, as was the case with the overall trial results. In 
the US subgroup, there was an important, significant 
(P=0.004) 30% relative and 2.6% absolute risk reduc-
tion in all-cause mortality (NNT, 39), with an interaction 
P value of 0.02 between the US and non-US subgroups.
Whereas the non-US subgroup also showed signifi-
cant reductions in the primary and key secondary com-
posite end  points, the US subgroup demonstrated 
particularly robust risk reductions. Formal statistical 
testing did not clearly show heterogeneity between 
the US and non-US subgroups for most end  points, 
and therefore the overall positive trial results apply to 
the entire population enrolled in REDUCE-IT, regard-
less of geography. However, it is reassuring that the 
results in the United States are at least as striking as 
Figure 1. Kaplan-Meier curves for the 
primary composite end point in the US 
subgroup. 
The y axis represents the cumulative incidence 
rate. Primary composite end point events were 
cardiovascular death, nonfatal myocardial 
infarction, nonfatal stroke, coronary revascular-
ization, or hospitalization for unstable angina. 
The curves were visually truncated at 5.7 years 
because a limited number of events occurred 
beyond that time point; all patient data were 
included in the analyses. *Estimated Kaplan-
Meier event rate at ≈5.7 years. HR indicates 
hazard ratio; and no. at risk, number of patients 
at risk for an event.
Figure 2. Kaplan-Meier curves for the key 
secondary composite end point in the US 
subgroup. 
The y axis represents the cumulative incidence 
rate. Key secondary composite end point events 
were cardiovascular death, nonfatal myocardial 
infarction, and nonfatal stroke. The curves were 
visually truncated at 5.7 years because a limited 
number of events occurred beyond that time 
point; all patient data were included in the 
analyses. *Estimated Kaplan-Meier event rate at 
≈5.7 years. HR indicates hazard ratio; and no. at 
risk, number of patients at risk for an event. 
Bhatt et al REDUCE-IT USA
Circulation. 2020;141:367–375. DOI: 10.1161/CIRCULATIONAHA.119.044440 February 4, 2020 373
ORIGINAL RESEARCH 
ARTICLE
the overall REDUCE-IT findings. Given prior positive 
randomized trials of various drugs and strategies that 
reported diminished efficacy or even lack of efficacy 
in the US subgroup, the results of the present analysis 
from REDUCE-IT provide confidence that US patients 
would derive at least as much benefit from icosapent 
ethyl as seen in the overall trial.
Tolerability and safety findings in the US subgroup 
were consistent with the full study population. The over-
all  tolerability of icosapent ethyl was virtually identical 
to that of placebo, with no significant differences in the 
rates of treatment-emergent adverse events or in serious 
treatment-emergent adverse events. In the United States, 
there was an increase in any bleeding with icosapent eth-
yl, but no significant difference in serious adverse events 
related to bleeding. There was an increase in the overall 
treatment-emergent adverse event rate of atrial fibrilla-
tion or flutter, but not in the category of serious adverse 
events of atrial fibrillation or flutter or the adjudicated 
end point of hospitalization ≥24 hours for atrial fibrilla-
tion or flutter. Therefore, the risk-benefit profile of icosa-
pent ethyl appears highly favorable. International guide-
lines have embraced the REDUCE-IT data10–13 and registry 
analyses show the data are generalizable to patients in 
typical clinical practice.14 An independent analysis using 
trial-level data found that icosapent ethyl was highly cost-
effective.15 Thus, the remaining challenge, as is often the 
case with randomized clinical trial data, is implementa-
tion of the REDUCE-IT results in daily clinical practice.
Limitations of this analysis include that REDUCE-
IT was not specifically powered to examine individual 
subgroups, including this prespecified subgroup of US 
Figure 3. Hierarchical testing of end points in the US subgroup. 
The prespecified plan for hierarchical testing of end points for the US subgroup. The rates of all end points including total mortality were significantly lower in the 
icosapent ethyl group than in the placebo group. HR indicates hazard ratio; and ITT, intention to treat.
Figure 4. Total mortality in the US sub-
group. 
Kaplan-Meier event curves for the end point of 
all-cause mortality in the US subgroup. The y 
axis represents the cumulative incidence rate. 
The curves were visually truncated at 5.7 years 
because a limited number of events occurred 
beyond that time point; all patient data were 
included in the analyses. *Estimated Kaplan-
Meier event rate at ≈5.7 years. HR indicates 
hazard ratio; and no. at risk, number of patients 
at risk for an event.
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patients. The statistical interaction terms for heteroge-
neity for the comparisons of US and non-US patients 
were not significant for most end points, and therefore 
differences in efficacy outcomes for the US patients are 
neither qualitative nor quantitative. Nevertheless, the 
data are informative and provide reassurance that the 
results seen in the United States are at least as strong as 
the results seen outside the United States and in the trial 
overall.
As seen in the overall REDUCE-IT population and 
in the non-US patients, icosapent ethyl 4 g/d signifi-
cantly reduced the primary and key secondary efficacy 
end points within the prespecified subgroup of patients 
randomized within the United States. The benefits in 
the US subgroup included significant reductions in all 
ischemic end points tested within the prespecified hier-
archical sequence, including all-cause mortality.
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